2 Stocks to Buy Hand Over Fist if a Stock Market Crash Is Coming

The article identifies Coca-Cola and Johnson & Johnson as recession-resistant dividend stocks, each having raised dividends for 64 consecutive years. Coca-Cola trades at 25.2x forward earnings versus a 21x consumer-staples average, reflecting a premium for its defensive beverage franchise. J&J's diversified pharmaceutical and medical-device businesses support resilience, although U.S. drug-price negotiations and talc litigation remain risks; it has proposed a $5.5B ovarian talc settlement and retains an AAA S&P credit rating.

Analysis

The relevant question is not whether KO and JNJ are defensive, but whether investors are being paid for that defensiveness. KO’s premium valuation leaves limited room for earnings disappointment: a weaker volume/mix outcome, higher promotional spend, or adverse FX can compress the multiple even if absolute earnings remain resilient. In a genuine growth scare over the next 1-3 months, KO should hold up better than discretionary consumer names, but it is unlikely to outperform if falling bond yields trigger a broad duration-led rally in higher-beta equities.

JNJ offers a more differentiated defensive setup because its earnings drivers are less tied to consumer elasticity and more to execution across pharmaceuticals and medtech. The principal 6-18 month issue is whether new-product growth and procedure-volume strength can offset mature-brand erosion and incremental U.S. pricing pressure; litigation resolution would remove a valuation overhang only if the final cash cost and payment structure are clearly bounded. A recession alone is not sufficient catalyst for either name—relative upside needs either a material earnings-guidance divergence versus cyclicals or a risk-off regime that rewards cash-flow certainty.

Contrarian view: defensive crowding can turn these into sources of funds if recession fears fade. KO is more exposed to de-rating risk because its multiple already embeds stability, while JNJ has a clearer path to multiple expansion if legal uncertainty narrows and pipeline execution exceeds conservative expectations. The better expression is therefore JNJ over KO, rather than an unhedged long in both names.

Key Decisions for Investors

• Initiate a 3-6 month pair: long JNJ / short KO in equal dollar amounts. Target 8-12% relative return from JNJ legal-overhang normalization and superior earnings optionality; exit if JNJ cuts full-year operational sales guidance or KO demonstrates sustained volume acceleration sufficient to support further multiple expansion.
• For defensive equity exposure, prefer JNJ accumulation on broad market risk-off days rather than chasing a headline-driven move. Size for a 6-18 month horizon; reassess if U.S. drug-pricing actions broaden materially beyond currently modeled products or if litigation cash requirements exceed the company’s expected funding capacity.
• Avoid adding KO solely as a recession hedge at its current premium without confirmation of improving organic volume and stable gross-margin outlook. A watch trigger for a tactical long is a 10-15% relative underperformance versus XLP accompanied by unchanged guidance; otherwise, use XLP for diversified staples exposure.
• Monitor the JNJ/KO relative chart around quarterly results: a widening gap in JNJ pharma growth versus expectations, combined with lower-than-expected talc reserve uncertainty, is the near-term catalyst for the pair; a soft medtech procedure backdrop is the key falsifier.